2-189057394-T-G
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PP2BP4_StrongBP6BS2
The NM_000393.5(COL5A2):āc.2263A>Cā(p.Thr755Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000304 in 1,613,598 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000393.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL5A2 | NM_000393.5 | c.2263A>C | p.Thr755Pro | missense_variant | 34/54 | ENST00000374866.9 | NP_000384.2 | |
COL5A2 | XM_011510573.4 | c.2125A>C | p.Thr709Pro | missense_variant | 37/57 | XP_011508875.1 | ||
COL5A2 | XM_047443251.1 | c.2125A>C | p.Thr709Pro | missense_variant | 39/59 | XP_047299207.1 | ||
COL5A2 | XM_047443252.1 | c.2125A>C | p.Thr709Pro | missense_variant | 38/58 | XP_047299208.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL5A2 | ENST00000374866.9 | c.2263A>C | p.Thr755Pro | missense_variant | 34/54 | 1 | NM_000393.5 | ENSP00000364000.3 | ||
COL5A2 | ENST00000618828.1 | c.1102A>C | p.Thr368Pro | missense_variant | 27/47 | 5 | ENSP00000482184.1 | |||
COL5A2 | ENST00000470524.2 | n.369A>C | non_coding_transcript_exon_variant | 7/8 | 5 |
Frequencies
GnomAD3 genomes AF: 0.000165 AC: 25AN: 151772Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251378Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135858
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461738Hom.: 0 Cov.: 33 AF XY: 0.00000963 AC XY: 7AN XY: 727190
GnomAD4 genome AF: 0.000165 AC: 25AN: 151860Hom.: 0 Cov.: 32 AF XY: 0.000202 AC XY: 15AN XY: 74196
ClinVar
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 07, 2014 | TAAD is a genetically heterogeneous disorder characterized by aortic dilatation, aneurysms, dissections and/or aneurysms of other major arteries. Approximately 4% of patients with autosomal dominant Ehlers-Danlos syndrome (EDS), classic type, have been reported to have a mutation in the COL5A2 gene (Malfait F et al., 2011). p.Thr755Pro (ACA>CCA): c.2263 A>C in exon 34 of the COL5A2 gene (NM_000393.3). The T755P variant in the COL5A2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Although T755P results in a non-conservative amino acid substitution of a polar Threonine with a non-polar, sterically constrained Proline, this substitution occurs at a position that is not well conserved across species. Consequently, twoin silico analysis programs predict T755P has a benign effect on the protein structure/function, while another predicts a damaging effect. In addition, there have been no nearby mutations reported in association with classic-type EDS, indicating this region of the protein may be tolerant of change. The T755P variant was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, however it was observed in 1/78 alleles (1.3%) in the dbSNP database (rs3435097). With the clinical and molecular information available at this time, we cannot definitively determine if T755P is a disease-causing mutation or a rare benign variantThis variant was found in TAAD - |
Familial thoracic aortic aneurysm and aortic dissection Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 30, 2024 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Ehlers-Danlos syndrome, classic type, 1 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at